Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3

GEAP202617026APending Publication Date: 2026-10-26MERCK SHARP & DOHME LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
GEAP202617026P0
Authority / Receiving Office
GE · GE
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-14
Filing Date
2024-12-12
Publication Date
2026-10-26
Patent Text Reader

Abstract

Abstract Azaindazole derivatives useful as inhibitors of NOD-like receptor 3 protein The invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, which are NLRP3 inhibitors and which can be used for the treatment, prevention, management, alleviation, control or suppression of NLRP3 mediated diseases. The compounds of the present invention can be used for the treatment, prevention or management of NLRP3 mediated diseases, disorders and conditions such as, but not limited to, obesity, nicrisis, pseudonicrisis, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies (DLB) and traumatic brain injury. (I)
Need to check novelty before this filing date? Find Prior Art